Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| BIIB | Biogen Inc. | 0.67% | 345.22 | 1.2% | $624.02m | |
| GILD | Gilead Sciences, Inc. | -3.53% | 72.92 | 0.9% | $510.71m | |
| CELG | Celgene Corporation | 0.24% | 90.37 | 1.2% | $496.41m | |
| AMGN | Amgen Inc. | 0.50% | 197.42 | 1.2% | $485.34m | |
| ILMN | Illumina, Inc. | -0.34% | 325.88 | 3.5% | $373.70m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.67% | 374.26 | 2.6% | $315.78m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.64% | 176.08 | 1.9% | $209.08m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.09% | 116.00 | 2.0% | $186.59m | |
| A | Agilent Technologies, Inc. | -1.28% | 64.66 | 1.5% | $159.27m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.52% | 130.25 | 16.6% | $142.46m | |
| NKTR | Nektar Therapeutics | 0.13% | 60.03 | 5.6% | $126.29m | |
| BLUE | Bluebird Bio, Inc. | 1.15% | 158.00 | 14.6% | $121.57m | |
| EXAS | Exact Sciences Corporation | 0.33% | 48.84 | 25.3% | $118.82m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.69% | 101.01 | 4.4% | $118.74m | |
| INCY | Incyte Corporation | 1.40% | 68.80 | 2.5% | $111.73m |
Company Profile
CareDx, Inc. operates as a transplant diagnostics company, which offers pre- and post-transplant continuum. It focuses on discovery, development, and commercialization of diagnostic surveillance solutions. Its product includes AlloMap, which aids clinicians in identifying heart transplant recipients with stable allograft function and AlloSure, which is a donor-derived cell free DNA test. The firm operates through two segments: Post-Transplant and Pre-Transplant. The Post-Transplant segment is engages in development of diagnostic solutions for transplant patients. The Pre-Transplant segment develops, manufactures, markets and sells products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.